Promising new combo aims to improve lung cancer treatment

NCT ID NCT05555732

Disease control Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug combination (datopotamab deruxtecan plus pembrolizumab) against standard treatment for advanced non-small cell lung cancer. It includes about 1,170 adults whose tumors have low PD-L1 levels and no specific gene changes. The goal is to see if the new combo helps people live longer without their cancer growing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 1,170 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2023

Expected to finish

May 2031

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: 1. Sign and date the Main ICF, prior to the start of any study- specific qualification procedures. Is willing and able to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions. 2. Adults ≥18 at the time the Main ICF is signed. (Follow local regulatory requirements if the legal age of adult voluntary consent for study participation is \>18 years old). 3. Has tumor with PD-L1 TPS \<50% as determined by PD-L1 IHC 22C3 pharmDx assay by central testing (minimum of 6 slides). PD-L1 expression results available at the same central laboratory from screening for the purpose of entry into another Dato-DXd study may be used for tissue screening purposes in this study as long as the subject has not been randomized/enrolled in the other study. 4. Has provided a formalin-fixed tumor tissue sample (minimum of 4 × 4-micron sections or block equivalent) for the measurement of TROP2 protein expression and for the assessment of other exploratory biomarkers. This tissue requirement is in addition to the tissue required for PD-L1 testing for tissue screening purposes. If a documented law or regulation prohibits (or does not approve) sample collection, then such sample will not be collected, and the subject is still eligible for the study. 5. Has not been treated with systemic anticancer therapy for advanced or metastatic non-squamous NSCLC. Subjects who received adjuvant or neoadjuvant therapy other than those listed in the exclusion criteria are eligible if the adjuvant/ neoadjuvant therapy was completed at least 6 months prior to the diagnosis of advanced/metastatic disease and should not have progressed on or within the 6 months of completion. 6. Has measurable disease based on local imaging assessment using RECIST v1.1; radiographic tumor assessment must be performed within 28 days before randomization. Key Exclusion Criteria: 1. Has received prior systemic treatment for advanced/metastatic NSCLC. 2. Has received prior treatment with any of the following, including in the adjuvant/neoadjuvant setting (for NSCLC): 1. Any agent, including an ADC, containing a chemotherapeutic agent targeting topoisomerase I 2. TROP2-targeted therapy 3. Any anti-PD-1, anti-PD-L1, or anti-programmed death-ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX40, CD137) 4. Any other ICIs Subjects who received adjuvant or neoadjuvant therapy other than those listed above are eligible if the adjuvant/neoadjuvant therapy was completed at least 6 months prior to the diagnosis of advanced or metastatic disease. 3. Has received a live vaccine within 30 days prior to the first dose of study treatment. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed. For any subject receiving an approved severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine, please follow the vaccine label and/or local guidance. The vaccine manufacturer and the date of administration should be recorded on the electronic case report form (Concomitant Medications page), as should any AEs relating to the vaccine (including hypersensitivity or allergies). Note: Any licensed SARS-CoV2 vaccine (including those authorized for emergency use) in a particular country is allowed in the study as long as the vaccine is an mRNA vaccine, replication-incompetent adenoviral vaccine, or inactivated vaccine. Such vaccines will be treated just as any other concomitant therapy. Investigational vaccines (ie, those not licensed or authorized for emergency use) are not allowed. 4. Has spinal cord compression or clinically active untreated CNS metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are radiologically stable (ie, without evidence of progression) for at least 2 weeks by repeat imaging (Note: Repeat imaging should be performed during study screening), clinically stable, and without requirement of steroid treatment for at least 7 days before the first dose of study drug. Note: A contrasted computed tomography (CT) scan or magnetic resonance imaging (MRI) scan of the brain at baseline (MRI with contrast preferred) is required for all subjects. For those subjects in whom CNS metastases are first discovered at the time of screening, the treating investigator must delay of study treatment to document stability of CNS metastases with repeat imaging at least 2 weeks later (in which case, repeat of all screening activity may be required). 5. Has uncontrolled or significant cardiovascular disease not controlled by maximal medical therapy, including: 1. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) interval \>470 msec regardless of sex (based on the 12-lead electrocardiogram \[ECG\] performed at screening). 2. Myocardial infarction within 6 months prior to Cycle 1 Day 1. 3. History of a serious cardiac arrhythmia requiring treatment 4. Uncontrolled angina pectoris within 6 months prior to Cycle 1 Day 1. 5. Left ventricular ejection fraction (LVEF) \<50% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before randomization. 6. New York Heart Association (NYHA) Class II-IV congestive heart failure (CHF) at screening. Subjects with a history of Class II to IV CHF prior to screening, must have returned to Class I CHF and have LVEF ≥50% (by either an ECHO or MUGA scan within 28 days before randomization) in order to be eligible. 7. Uncontrolled hypertension (resting systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mmHg within 28 days before randomization that is not resolved despite maximal medical therapy). 6. Clinically severe pulmonary compromise as judged by the investigator resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (eg, pulmonary emboli diagnosed within 3 months of Cycle 1 Day 1, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion, etc) or any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement (eg, rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc), or prior complete pneumonectomy.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic non-small cell lung cancer

Contacts and locations

Locations

Adana Acibadem Hospital

Seyhan, Turkey (Türkiye)
Affiliated Cancer Hospital and Insititute of Guangzhou Medical University

Guangzhou, 510095, China
Akdeniz University Hospital

Antalya, 7070, Turkey (Türkiye)
American Oncology Partners of Maryland

Bethesda, Maryland, 20817, United States
Amphia Ziekenhuis

Breda, 4819 EV, Netherlands
An Hui Cancer Hospital

Hefei, China
Ankara Bilkent City Hospital

Ankara, 6800, Turkey (Türkiye)
Aphm - Hopital Nord

Marseille, 13015, France
Arizona Oncology Associates, Pc - Nahoa

Prescott Valley, Arizona, 86314, United States
Asan Medical Center

Seoul, 05505, South Korea
Asst Sette Laghi

Varese, 21100, Italy
Astera Cancer Care

East Brunswick, New Jersey, 08816, United States
Az Maria Middelares - Campus Maria Middelares

Ghent, 9000, Belgium
Az Nikolaas

Sint-Niklaas, 9100, Belgium
Azienda Ospedaliera Universitaria Integrata Verona Ospedale Borgo Roma Crc - Centro Ricerche Clinich

Verona, 37134, Italy
Azienda Ospedaliero - Universitaria San Luigi Gonzaga

Orbassano, 10043, Italy
Barts Health NHS Trust

London, EC1A 7BE, United Kingdom
Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Bioclinic Thessaloniki (Galinos Clinic)

Thessalonki, 54622, Greece
Bkmk Hospital

KecskemĂŠt, 6000, Hungary
CHU de Quebec -Universite Laval Hopital de L'Enfant-Jesus

Québec, G1J 1Z4, Canada
CHU de Rennes - Hopital Pontchaillou

Rennes, 35033, France
CHUO

Ourense, 32005, Spain
CRSA/ St Andrews Hospital

Adelaide, 5000, Australia
Cancer Care Centers of Brevard, Inc.

Palm Bay, Florida, 32901, United States
Cancer Specialist of North Florida

Jacksonville, Florida, 32256, United States
Cangzhou Peoples Hospital

Cangzhou, 061000, China
Centre Hospitalier Universitaire, CHU, de Poitiers

France, 86021, France
Centre Leon Berard

Lyon, 69008, France
Centre hospitalier Jolimont-Lobbes

Haine-Saint-Paul, Belgium
Centro Polivalente de Asistencia E Investigacion Clinica Cer San Juan

San Juan, 5400, Argentina
Centro de Estudios Clinicos Saga Spa

Santiago, 7500653, Chile
Centro de Estudos E Pesquisa de Hematologia E Oncologia - Cepho

Santo André, 09060-870, Brazil
Centro de Investigacion Clinica de Oaxaca CICLO

Oaxaca City, Mexico
Centro de Investigacion Pergamino Sa

Pergamino, B2700, Argentina
Centro de Investigaciones Clinicas Vina Del Mar

ViĂąa Del Mar, 254-0488, Chile
Centro de Investigaciones Clinicas. Clinica Viedma S.A.

Viedma, 8500, Argentina
Centro de Investigaciones Medicas y Desarrollo LC SRL

Buenos Aires, Argentina
Centrul de Oncologie Sfantu Nectarie

Craiova, 200745, Romania
Centrum Terapii Wspolczesnej

Lodz, 90-338, Poland
Changhua Christian Hospital

Changhua, 500, Taiwan
Chiang Mai University CMU - Maharaj Nakhon Chiang Mai Hospital Nakorn Chiang Mai Hospital

Chiang Mai, 50200, Thailand
China Medical University Hospital

Hsia, Taiwan
Chongqing University Cancer Hospital

Chongqing, 400030, China
Chu de Bordeaux - Hopital Saint Andre

Bordeaux, 33075, France
Chu de Montpellier

Montpellier, 34295, France
Chu de Nantes

Nantes, 44000, France
Chungbuk National University Hospital

Cheongju-si, 28644, South Korea
Cliniques Saint Pierre Ottignies (CSPO)

Ottignies, Belgium
Clnica Lacks

Pelotas, 96020-080, Brazil
Clínica de Neoplasias Litoral Ltda

ItajaĂ-, 88301-220, Brazil
Compassionate Cancer Care Medical Group

Riverside, California, 92501, United States
Cryptex Investigacion Clinica Sa de Cv

Cuauhtémoc, Mexico
Dana Farber At Milford Regional Cancer Center

Milford, Massachusetts, 01757, United States
Dana Farber Brigham Cancer Center

Foxborough, Massachusetts, 02035, United States
Dana Farber Cancer Institute At St. Elizabeth'S Medical Center

Brighton, Massachusetts, 02135, United States
Dana Farber Cancer Institute; Inv Drg Svc Pharm

Boston, Massachusetts, 02215, United States
Dana Farber/Bwcc in Affiliation With South Shore Hospital

South Weymouth, Massachusetts, 02190, United States
Dokkyo Medical University Hospital

Tochigi, 321-0293, Japan
Ege Universitesi Gogus Hastaliklari Poliklinigi

Bornova-Izmir, Turkey (Türkiye)
Emory University - Winship Cancer Institute Wci

Atlanta, Georgia, 30322-1013, United States
Euromedica General Clinic of Thessaloniki

Thessaloniki, 546 45, Greece
Evangelische Lungenklinik Berlin

Berlin, 13125, Germany
External pharmacy Fortuna Herstellung GmbH of main site Universitaetsmedizin Mannheim

Mannheim, Germany
FN Brno Klinika Nemoci Plicnich a TBC

Brno, 63500, Czechia
Faculty of Medicine Chulalongkorn University

Bangkok, 10330, Thailand
Fakultni nemocnice Olomouc FNOL

Olomouc, 779 00, Czechia
Fejer Megyei Szent Gyorgy Korhaz Pulmonologiai Osztaly

Székesfehérvár, 8000, Hungary
First Affiliated Hospital of Medical College of Jilin University

Changchun, 130000, China
Flinders Medical Centre (Fmc)

Bedford Park, 5042, Australia
Florida Cancer Specialists - South

Fort Myers, Florida, 33901, United States
Florida Cancer Specialists-North

St. Petersburg, Florida, 33705, United States
Fudan University Shanghai Cancer Center

Shanghai, 200032, China
Fujian Medical University - Union Hospital Foochow Christian Union Hospital

Fuzhou, 350001, China
Fundacao Champalimaud

Lisbon, 1400-038, Portugal
Fundacion Arturo Lopez Perez

Santiago, Chile
Fundacion CENIT para la investigacion en Neurociencias

Ciudad Autonoma de Buenos Aire, 1125, Argentina
Fundaco Universidade de Caxias Do Sul- Instituto de Pesquisas Em Saude Ips-Ucs

Caxias do Sul, 95070-560, Brazil
Gyeongsang National University Hospital

Jinju-si Gyeongsangnam-do, 52727, South Korea
Haikou Peoples Hospital

Haikou, 570208, China
Harbin Medical University Cancer Hospital

Harbin, 150081, China
Health Pharma Professional Research S.A de C.V.

Mexico City, Mexico
Henan Cancer Hospital

Zhengzhou, 450003, China
Hetenyi G Korhaz, Onkologiai Kozpont

Szolnok, 5007, Hungary
Hoag Memorial Hospital Prebyterian

Newport Beach, California, 92663, United States
Hopital Jean Minjoz - CHU de Besancon

Besançon, 25000, France
Hopital Lyon Sud

Lyon, 69003, France
Hopital Prive Du Confluent

Nantes, 44277, France
Hosp Univ Virgen Macarena

Seville, 41009, Spain
Hospital CUF Porto

Porto, Portugal
Hospital Civil de Guadalajara Fray Antonio Alcalde

Guadalajara, Mexico
Hospital Clinic I Provincial de Barcelona

Barcelona, 8036, Spain
Hospital Clinico San Carlos

Madrid, 28040, Spain
Hospital Erasto Gaertner

Curitiba, 81520-060, Brazil
Hospital General Universitario Gregorio Marañon

Madrid, 28007, Spain
Hospital Regional Universitario Malaga

Málaga, 29011, Spain
Hospital Universitario Arnau de Vilanova

Lleida, 25198, Spain
Hospital Universitario Fundacion Jimenez Diaz

Madrid, 28040, Spain
Hospital Universitario Miguel Servet

Zaragoza, 50009, Spain
Hospital Universitario Virgen de Valme

Seville, 41014, Spain
Hospital Universitario y Politecnico de La Fe

Valenica, 46026, Spain
Hospital da Luz

Lisbon, 1500-650, Portugal
Hospital de La Comunidad

Mar del Plata, 7600, Argentina
Hubei Cancer Hospital

Wuhan, 430079, China
Hunan Cancer Hospital

Changsha, 410011, China
Hyogo Medical University Hospital

Hyōgo, 663-8501, Japan
Hôpital Foch

Suresnes, 92150, France
IFO Regina Elena

Rome, Italy
II Klinika Chorob Pluc i Gruzlicy

Bialystok, 15-540, Poland
IPO Porto Francisco Gentil, E.P.E.

Porto, 4150-001, Portugal
Illinois Cancer Specialists

Niles, Illinois, 60714, United States
Inner Mongolia Medical University- the Affiliated Hospital

Hohhot, 010050, China
Institut Curie

Paris, 75005, France
Institut Paoli Calmettes

Marseille, 13009, France
Institute of Oncology Prof. Dr. Ion Chiricuta

Cluj-Napoca, 400015, Romania
Instituto Alexander Fleming

Buenos Aires, Argentina
Instituto Do Cancer Brasil - Unidade Taubate

Taubaté, 12030-200, Brazil
Instituto Nacional de Cancerologia

Mexico City, Mexico
Instituto Nacional de Căncer - Inca

Rio de Janeiro, 20231-050, Brazil
Instituto de Ensino E Pesquisa Sao Lucas

São Paulo, 01236-030, Brazil
Instituto de Oncologia de Rosario

Rosario, 2000DSK, Argentina
Instytut Centrum Zdrowia Matki Polki (Iczmp)

Lodz, 93-338, Poland
Ironwood Cancer and Research Centers

Chandler, Arizona, 85224, United States
Istanbul Medeniyet University Medical Faculty

Istanbul, 34093, Turkey (Türkiye)
Istituto Di Candiolo Irccs

Candiolo, 10060, Italy
Iwakuni Clinical Center

Yamaguchi, 740-8510, Japan
Jeroen Bosch Ziekenhuis Jbz

's-Hertogenbosch, 5200 ME, Netherlands
Jessa Hospital

Hasselt, 3500, Belgium
Jiamusi Cancer Hospital

Jiamusi, 154007, China
Jilin Cancer Hospital

Changchun, 130000, China
Juntendo University Hospital

Tokyo, 113-8431, Japan
Kanagawa Cancer Center

Kanagawa, 241-8515, Japan
Kanazawa University Hospital

Ishikawa, 920-8641, Japan
Kansai Medical University Hospital

Osaka, 573-1191, Japan
Kantonsspital Baselland

Liestal, 4410, Switzerland
Kantonsspital St. Gallen

Sankt Gallen, 9007, Switzerland
Karl Landsteiner Institut Fã¼R Lungenforschung Und Pneumologische Onkologie C/O Klinik Floridsdorf

Vienna, 1210, Austria
Khon Kaen University - Faculty of Medicine-Srinagarind Hospital

Nonthaburi, 40002, Thailand
Kitasato University hospital

Kanagawa, 252-0375, Japan
Klinikum Chemnitz

Chemnitz, 9116, Germany
Klinikum Esslingen Gmbh

Esslingen am Neckar, 73730, Germany
Klinikum Klagenfurt Pulmologie

Klagenfurt, 9020, Austria
Koo Foundation Sun Yat-Sen Cancer Center

Taipei, 112, Taiwan
Kurume University Hospital

Fukoka, 830-0011, Japan
Kyungpook National University Chilgok Hospital

Daegu, 41404, South Korea
Kyushu Cancer Center

Fukuoka, 811-1395, Japan
Kyushu University Hospital

Fukuoka, 812-0054, Japan
Landeskrankenhaus Feldkirch

Feldkirch, 6800, Austria
Leiden University Medical Center

Leiden, 2333ZA, Netherlands
Liaoning Cancer Hospital & Institute

Shenyang, 110042, China
Linkou Chang Gung Memorial Hospital

Taoyuan, 333, Taiwan
Linyi Cancer Hospital

Linyi, 276000, China
Ludwig-Maximilians University Hospital of Munich

Munich, 80336, Germany
Maria Sklodowska-Curie National Research Institute of Oncology

Warsaw, 02-778, Poland
Maryland Oncology Heamtology P.A.

Columbia, Maryland, 21044, United States
Med Polonia Sp. Z O.O.

Poznan, 60-693, Poland
Medical Park Seyhan Hospital

Etimesgut Ankara, 6790, Turkey (Türkiye)
Medipol Mega University Hospital

Bağcılar, 34214, Turkey (Türkiye)
Memorial Ankara Hospital

Cankaya/Ankara, 6520, Turkey (Türkiye)
Metropolitan Hospital

Neo Faliro, 18547, Greece
Metropolitan Hospital - Athens

Athens, Greece
NHO Kinki-Chuo Chest Medical Center

Osaka, 591-8555, Japan
NHO Shikoku Cancer Center

Ehime, Japan
National Cancer Center

Goyang-si, 10408, South Korea
National Cheng Kung University Hospital

Tainan, 704, Taiwan
National Koranyi Institute For Pulmonology

Budapest, 1121, Hungary
National Taiwan University Hospital

Taipei, 10055, Taiwan
Niigata Cancer Center Hospital

Niigata, 951-8566, Japan
North Shore Hematology Oncology Associates

Patchogue, New York, 11772, United States
North Shore Hematology Oncology Associates DBA NY Cancer and Blood Specialists

Port Jefferson Station, New York, 11776, United States
North Shore Hematology Oncology Associates dba NY Cancer and Blood Specialists - Bronx

The Bronx, New York, 10469, United States
North Shore Hematology Oncology Associates dba NY Cancer and Blood Specialists- New Hyde Park

New Hyde Park, New York, 11042, United States
ONCOVIDA

Santiago, 7500000, Chile
Olympion Hospital

Pátrai, 26443, Greece
Onco Clinic Consult Sa

Craiova, 200094, Romania
Oncocenter Oncologie Clinica S.R.L

Timișoara, 300166, Romania
Oncocentro Apys

Viña del Mar, Chile
Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda

Ijuí, 98700-000, Brazil
Orlandi Oncologia

Santiago, 7500713, Chile
Osaka International Cancer Institute

Osaka, 540-0008, Japan
Osaka Toneyama Medical Center

Osaka, 560-8552, Japan
Ospedale S. Maria Della Misericordia

Udine, 33100, Italy
Ospedale San Luca

Lucca, Italy
PSEHOG (Peninsula and South Eastern Haematology and Oncology Group)

Frankston, 3199, Australia
Peking University Cancer Hospital Beijing Cancer Hospital Beijing Institute For Cancer Research

Beijing Sheng, 100142, China
Peking University Peoples Hospital

Beijing, 100044, China
Personal Oncologia de Precisao - Cenantron

Belo Horizonte, 30130 090, Brazil
Prince of Songkla University PSU - Faculty of Medicine

Hat Yai, 90110, Thailand
Prince of Wales Hospital / The Chinese University of Hong Kong

Hong Kong, 99999, Hong Kong
Princess Alexandra Hospital

Woolloongabba, QLD 4102, Australia
Providence Regional Cancer System

Lacey, Washington, 98503, United States
Queen Mary Hospital

Pok Fu Lam, 999077, Hong Kong
Ramathibodi Hospital

Bangkok, 10400, Thailand
Reformatus Pulmonologiai Centrum

Törökbálint, Hungary
Regional Cancer Care Associates LLC

Hackensack, New Jersey, 07601, United States
Ronald Reagan UCLA Medical Center

Santa Monica, California, 90404, United States
Run Run Shaw Hospital, Zhejiang University School of Medicine

Hangzhou, 310000, China
SC Oncomed SRL

Jud Timis, Romania
SPSK4, Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie

Lublin, 20-954, Poland
Sainte-Catherine Institut du Cancer Avignon-Provence

Avignon, France
Saiseikai Matsusaka Municipal Hospital

Mie, 515-8544, Japan
Samsung Medical Center

Gangnam-Gu, 6351, South Korea
Sanatorio Britanico

Rosario, Argentina
Sanatorio Parque

Rosario, S2000DSV, Argentina
Sansum Clinic

Santa Barbara, California, 93105, United States
Santa Casa de Misericordia de Porto Alegre

Porto Alegre, 90050-170, Brazil
Sendai Kousei Hospital

Miyagi, 981-0914, Japan
Seoul National University Bundang Hospital

Seongnam-si, 13620, South Korea
Shanghai Chest Hospital

Shanghai, 200030, China
Siriraj Hospital

Bangkok, 10700, Thailand
Social Welfare Organization Saiseikai Imperial Gift Foundation, Inc. Saiseikai Kumamoto Hospital

Kumamoto, 861-4193, Japan
Sotiria General Hospital of Chest Diseases

Athens, 11527, Greece
Southern Cancer Center Pc

Daphne, Alabama, 36526, United States
Southern Medical Day Care Centre

Wollongong, 2500, Australia
Spital Sts Ag

Thun, 3600, Switzerland
St George Public Hospital

Kogarah, 2217, Australia
St. Luke's Hospital

Thessaloniki, Greece
Taichung Veterans General Hospital

Taichung, 40705, Taiwan
Taipei Veterans General Hospital

Taipei, 112, Taiwan
Teine Keijinkai Hospital

Hokkaido, 006-0811, Japan
Tenon Hospital

Paris, 75020, France
Texas Oncology, P.A.

McAllen, Texas, 78503, United States
Texas Oncology, P.A.

Sugar Land, Texas, 77479, United States
Texas Oncology-Tyler

Tyler, Texas, 75702, United States
The Cancer Institute Hospital of JFCR

Tokyo, 135-0063, Japan
The Catholic Univ. of Korea, Seoul St. Marys Hospital

Seoul, 6591, South Korea
The First Affiliate Hospital of Xi'An Jiaotong University

Xi'an, 710061, China
The First Affiliated Hospital Sun Yat-Sen University

Guangzhou, 510080, China
The First Affiliated Hospital of College of Medicine Zhejiang University

Hangzhou, 310003, China
The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, 510120, China
The First Affiliated Hospital of Nanchang University

Nanchang, 330006, China
The First Affiliated Hosptial of Xinjiang Medical University

Ürümqi, 830000, China
The Second Peoples Hospital of Neijiang

Neijiang Shi, 641000, China
Tianjin Medical University General Hospital

Tianjin, 300052, China
Toho University Omori Medical Center

Tokyo, 143-8540, Japan
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital

Tokyo, 113-0021, Japan
Tri-Service General Hospital

Taipei, 11490, Taiwan
Tuen Mun Hospital

Hong Kong, 999077, Hong Kong
UCHealth Memorial Hospital

Colorado Springs, Colorado, 80909, United States
Union Hospital of Tongji Medical College Huazhong University of Science and Technology

Wuhan, 430022, China
Universitaetsklinikum Essen

Essen, 45147, Germany
Universitaetsklinikum Freiburg

Freiburg im Breisgau, 79106, Germany
University General Hospital of Heraklion

Heraklion, 71110, Greece
University Hospital Giessen, ZIM IV

Giessen, Germany
University Hospital Kyoto Prefectual University of Medicine

Kyoto, 602-8566, Japan
University Hospital Mănster

Münster, 48149, Germany
University Hospital of Ioannina Uhi

Ioannina, 45500, Greece
University of Electronic Science Technology of China UESTC - Sichuan Cancer Hospital Institute SIC

Chengdu, 610041, China
Ut Health San Antonio

San Antonio, Texas, 78229, United States
Utah Cancer Specialists IHO Corp

Salt Lake City, Utah, 84106, United States
VA Puget Sound Health Care System

Seattle, Washington, 98108, United States
Vall Hebron University Hospital

Barcelona, 08035, Spain
Veszprem Megyei Tudogyogyintezet Farkasgyepu

Farkasgyepű, 8582, Hungary
Vseobecna Fakultni Nemocnice VFN

Brno, 63500, Czechia
Woodlands Medical Specialists, Pa

Pensacola, Florida, 32503, United States
Xiangyang Central Hospital

Xianyang, 441021, China
Yamaguchi-Ube Medical Center

Yamaguchi, 755-0241, Japan
Yamanashi Prefectural Central Hospital

Yamanashi, 400-8506, Japan
Yonsei University Health System - Severance Hospital

Seoul, 3722, South Korea
Zhongda Hospital, Southeast University

Nanjing, 210009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.